Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Dec 13, 2017

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special oil rich in Omega-7 fatty acids, specifically palmitoleic acid, on heart health and feelings of fullness in healthy adults. Researchers believe this oil, found in certain fish and nuts, may be beneficial for metabolism and cardiovascular health. The trial aims to gather more information to understand these potential benefits.

To join the study, participants need to be at least 18 years old and in good health, with no history of heart disease. Women must not be pregnant or breastfeeding. Those who participate will visit the research site four times over 24 weeks for various tests, including blood draws and health monitoring. They will also take four capsules of the Omega-7 oil daily and keep a food and exercise journal. Participants will be compensated for their time upon completing the study.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Male and female participants 18 years of age or above.
• • Subject must be healthy, with no known history of cardiovascular disease.
• • Post-menopausal or women of childbearing potential must be non-lactating and using an effective form of birth control during the course of the study.
• • Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations.
• • Subjects with triglyceride levels above 100 mg/dL
• EXCLUSION CRITERIA:
• • Pregnancy, planned pregnancy (within the study period), or women currently breastfeeding.
• • Subjects with allergy or known hypersensitivity to fish, omega-3-acid ethyl esters, omega-7 ethyl esters, other related drugs, or any component of study drugs
• • Subjects with weight changes greater than 20% over the past 3 months.
• • Subjects planning a significant change in diet or exercise levels.
• • Subjects already consuming more than 2 g per day of MUFA, PUFA or other forms of fatty acid supplement if determined by the investigator as having a potential to interfere in the data quality or patient safety.
• • Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.
• • Subjects with any acute and life-threatening condition, such but not limited to as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism as per investigator assessment.
• • Subjects taking supplements or medications that affect lipoproteins for at least the past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins, Niacin or PCSK9 inhibitors.
• • Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for \>4 weeks.
• • Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion.
• • Anticipated surgery during the study period.
• • Liver enzymes (AST or ALT) levels above 3x upper limit of normal.
• • Blood donation in the last 2 weeks or planned blood donation during the study.
• • Subjects requiring regular transfusions for any reason.
• • Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data or for not complying with protocol directions.
• • Abnormal baseline laboratory values that are considered not clinically significant by the PI will not exclude the subject.